Compare Organon & Co. Common Stock (OGN) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Shell PLC — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Shell PLC trades at $104.37 (market cap $294.95B). The key difference: Shell PLC is far larger — about 81.7× Organon & Co. Common Stock's market cap, and Shell PLC pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Shell PLC for 91 Days on average.
| OGN | SHEL | |
|---|---|---|
Market Cap | $3.61B | $294.95B |
Volume | 1,808,049 | 6,021,309 |
Sector | Health | Energy |
52-Week High | $13.81 | $103.58 |
52-Week Low | $5.70 | $70.31 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $11.03B | $336.65B |
Dividend Yield | 0.58% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Shell (SHEL) trades at $102.99, up 1.38% on the day, near its 52-week high. The stock shows strong technical momentum with bullish moving averages, though oscillators indicate overbought conditions. Fundamentally, the company delivered earnings beats in Q1 and Q2 2026, with a forward P/E of 11.39 suggesting reasonable valuation. Recent news highlights strategic LNG expansion, including the Phase 2 approval for LNG Canada, positioning Shell for long-term growth in global gas markets.
The outlook for Shell remains positive, supported by robust cash flows, strategic investments in LNG, and a favorable analyst consensus with 62% buy ratings. Key risks include exposure to volatile oil prices and execution challenges in major projects. The stock offers value through dividends and growth potential, but investors should monitor energy market dynamics and project timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
